Direct oral anticoagulants reduced total bleeding risk by 92% compared to warfarin in patients with atrial fibrillation and chronic obstructive pulmonary disease (OR 0.08, 95% CI 0.01–0.50).
Cohort (n=11,132)
Yes
Do direct oral anticoagulants reduce bleeding and all-cause death compared to warfarin in patients with atrial fibrillation and chronic obstructive pulmonary disease?
In patients with atrial fibrillation and COPD, DOACs significantly reduce the risk of total and minor bleeding compared to warfarin, and may offer a survival benefit in those with renal impairment.
Effect estimate: OR 0.08 (95% CI 0.01–0.50)
In AF with comorbid COPD, DOACs minimize bleeding versus warfarin and may confer survival benefit in renal impairment. Choice among DOACs should consider differential bleeding risk.
Zhao et al. (Thu,) conducted a cohort in Patients with atrial fibrillation and chronic obstructive pulmonary disease undergoing oral anticoagulant therapy (n=11,132). Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Total bleeding (all bleeding events including major and minor) (OR 0.08, 95% CI 0.01–0.50). Direct oral anticoagulants reduced total bleeding risk by 92% compared to warfarin in patients with atrial fibrillation and chronic obstructive pulmonary disease (OR 0.08, 95% CI 0.01–0.50).